Cargando…

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novo, Salvatore, Fazio, Giovanni, Raccuglia, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978536/ https://www.ncbi.nlm.nih.gov/pubmed/27713228 http://dx.doi.org/10.3390/ph2030118

Ejemplares similares

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124
por: Novo, Salvatore, et al.
Publicado: (2011)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

Structural Predestination of Individual Diversity in the Course and Severity of Infectious Diseases
por: Rumyantsev, Sergey N.
Publicado: (2002)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19
por: Najafi, Narges, et al.
Publicado: (2022)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
por: Rossi, Gian Paolo, et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
por: Braude, Philip, et al.
Publicado: (2020)

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
por: Byttebier, Geert, et al.
Publicado: (2021)

Aliskiren: An orally active renin inhibitor
por: Wal, Pranay, et al.
Publicado: (2011)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
por: Flacco, Maria Elena, et al.
Publicado: (2020)

NO EXCESS MORTALITY ASSOCIATED WITH CONCOMITANT ACE INHIBITOR OR ARB USE IN HOSPITALIZED PATIENTS WITH COVID-19
por: Annie, Frank H., et al.
Publicado: (2021)

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008
por: Bian, Boyang, et al.
Publicado: (2010)

La déclaration de foi sur la prédestination par l'Eglise réformée du Japon /
por: Morikawa, Hajime
Publicado: (1996)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
por: Sureshkumar, Kalathil K
Publicado: (2008)

The concern about ACE/ARB and COVID-19: Time to hold your horses!
por: Pergolizzi, Joseph V., et al.
Publicado: (2020)

Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
por: Kalyesubula, Robert, et al.
Publicado: (2014)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Just a few days left
Publicado: (2005)

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
por: McMurray, John J.V., et al.
Publicado: (2012)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Impact of Beta-blocker, ACE Inhibitor, and ARB therapy on thoracic aorta wall shear stress in bicuspid aortic valve patients
por: McGee, Katherine, et al.
Publicado: (2016)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
por: Sieńko, Jerzy, et al.
Publicado: (2020)

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2
por: Emilsson, Valur, et al.
Publicado: (2020)

Aliskiren and the dual complement inhibition concept
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Direct Renin Inhibition: Focus on Aliskiren
por: Pool, James L.
Publicado: (2007)

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
por: Chung, Mina K., et al.
Publicado: (2020)

Peripheral artery disease: potential role of ACE-inhibitor therapy
por: Coppola, Giuseppe, et al.
Publicado: (2008)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Physician Conformity and Patient Adherence to ACE Inhibitors and ARBs in Patients With Diabetes, With and Without Renal Disease and Hypertension, in a Medicaid Managed Care Organization
por: Cooke, Catherine E., et al.
Publicado: (2006)

Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression
por: Alzarea, Sami I., et al.
Publicado: (2022)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California
por: Rubin, Samuel J. S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmupujru5m0jngf8jfkcoosjph